Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 198

The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.

Pharmacodynamics, Pharmacokinetics, Safety, and Tolerability of Albiglutide, a Long-Acting Glucagon-Like Peptide-1 Mimetic, in Patients with Type 2 Diabetes

Open access
Matthews, Jessica E., Stewart, Murray W., De Boever, Erika H., Dobbins, Robert L., Hodge, Rebecca J., Walker, Susan E., Holland, M. Claire, Bush, Mark A., for the Albiglutide Study Group·2008·The Journal of Clinical Endocrinology & Metabolism

Abstract

CONTEXT: Native glucagon-like peptide-1 increases insulin secretion, decreases glucagon secretion, and reduces appetite but is rapidly inactivated by dipeptidyl peptidase-4. Albiglutide is a novel dipeptidyl peptidase-4-resistant glucagon-like peptide-1 dimer fused to human albumin designed to have sustained efficacy in vivo. OBJECTIVES: The objectives were to investigate pharmacodynamics, pharmacokinetics, safety, and tolerability of albiglutide in type 2 diabetes subjects. METHODS: In a single-blind dose-escalation study, 54 subjects were randomized to receive placebo or 9-, 16-, or 32-mg albiglutide on d 1 and 8. In a complementary study, 46 subjects were randomized to a single dose (16 or 64 mg) of albiglutide to the arm, leg, or abdomen. RESULTS: Significant dose-dependent reductions in 24-h mean weighted glucose [area under the curve((0-24 h))] were observed, with placebo-adjusted least squares means difference values in the 32-mg cohort of -34.8 and -56.4 mg/dl [95% confidence interval (-54.1, -15.5) and (-82.2, -30.5)] for d 2 and 9, respectively. Placebo-adjusted fasting plasma glucose decreased by -26.7 and -50.7 mg/dl [95% confidence interval (-46.3, -7.06) and (-75.4, -26.0)] on d 2 and 9, respectively. Postprandial glucose was also reduced. No hypoglycemic episodes were detected in the albiglutide cohorts. The frequency and severity of the most common adverse events, headache and nausea, were comparable with placebo controls. Albiglutide half-life ranged between 6 and 7 d. The pharmacokinetics or pharmacodynamic of albiglutide was unaffected by injection site. CONCLUSIONS: Albiglutide improved fasting plasma glucose and postprandial glucose with a favorable safety profile in subjects with type 2 diabetes. Albiglutide's long half-life may allow for once-weekly or less frequent dosing.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1210/jc.2008-1518

Cites

11 of 11 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 11 references

Research works printed but not linked: 21

  1. Nathan, 2006, Management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes., Diabetes Care, 29, 1963, 10.2337/dc06-9912 · DOI · Paper page
  2. Scheen, 1998, Oral antidiabetic agents. A guide to selection., Drugs, 55, 225, 10.2165/00003495-199855020-00004 · DOI
  3. Kreymann, 1987, Glucagon-like peptide-1 7–36: a physiological incretin in man., Lancet, 2, 1300, 10.1016/S0140-6736(87)91194-9 · DOI · Paper page
  4. Naslund, 1999, GLP-1 slows solid gastric emptying and inhibits insulin, glucagon, and PYY release in humans, Am J Physiol, 277, R910
  5. Drucker, 2003, Glucagon-like peptides: Regulators of cell proliferation, differentiation, and apoptosis., Mol Endocrinol, 17, 161, 10.1210/me.2002-0306 · DOI · Paper page
  6. Orskov, 1993, Biological effects and metabolic rates of glucagonlike peptide-1 7–36 amide and glucagonlike peptide-1 7–37 in healthy subjects are indistinguishable., Diabetes, 42, 658, 10.2337/diab.42.5.658 · DOI · Paper page
  7. Green, 2007, Incretin hormone mimetics and analogues in diabetes therapeutics., Best Pract Res Clin Endocrinol Metab, 21, 497, 10.1016/j.beem.2007.09.003 · DOI
  8. Brubaker, 2007, Incretin-based therapies: mimetics versus protease inhibitors., Trends Endocrinol Metab, 18, 240, 10.1016/j.tem.2007.06.005 · DOI
  9. Boyle, 2007, Application of incretin mimetics and dipeptidyl peptidase IV inhibitors in managing type 2 diabetes mellitus, J Am Osteopath Assoc, 107, S10
  10. Drucker, 2006, The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes., Lancet, 368, 1696, 10.1016/S0140-6736(06)69705-5 · DOI · Paper page
  11. Chuang, 2002, Pharmaceutical strategies utilizing recombinant human serum albumin., Pharm Res, 19, 569, 10.1023/A:1015396825274 · DOI · Paper page
  12. Dennis, 2002, Albumin binding as a general strategy for improving the pharmacokinetics of proteins., J Biol Chem, 277, 35035, 10.1074/jbc.M205854200 · DOI · Paper page
  13. Baggio, 2004, A recombinant human glucagon-like peptide (GLP)-1-albumin protein (albugon) mimics peptidergic activation of GLP-1 receptor-dependent pathways coupled with satiety, gastrointestinal motility, and glucose homeostasis., Diabetes, 53, 2492, 10.2337/diabetes.53.9.2492 · DOI · Paper page
  14. Bloom, 2003, Albugon fusion protein: a long-acting analog of GLP-1 that provides lasting antidiabetic effect in animals, Diabetes Care, 52, A112
  15. Ou, 2003, Pharmacokinetic and pharmacodynamic analysis of albugon, a long-acting analog of glucagon-like peptide-1 in mice and monkeys, AAPS Pharm Sci, 5, 5263
  16. Holst, 2008, Glucagon-like peptide-1, glucose homeostasis and diabetes., Trends Mol Med, 14, 161, 10.1016/j.molmed.2008.01.003 · DOI · Paper page
  17. Kolterman, 2005, Pharmacokinetics, pharmacodynamics, and safety of exenatide in patients with type 2 diabetes mellitus., Am J Health Syst Pharm, 62, 173, 10.1093/ajhp/62.2.173 · DOI · Paper page
  18. Larsen, 2001, Glucagon-like peptide-1 infusion must be maintained for 24 h/day to obtain acceptable glycemia in type 2 diabetic patients who are poorly controlled on sulphonylurea treatment., Diabetes Care, 24, 1416, 10.2337/diacare.24.8.1416 · DOI · Paper page
  19. Damholt, 2006, An open-label, parallel group study investigating the effects of age and gender on the pharmacokinetics of the once-daily glucagon-like peptide-1 analogue liraglutide., J Clin Pharmacol, 46, 635, 10.1177/0091270006288215 · DOI
  20. Fineman, 2004, Effectiveness of progressive dose-escalation of exenatide (exendin-4) in reducing dose-limiting side effects in subjects with type 2 diabetes., Diabetes Metab Res Rev, 20, 411, 10.1002/dmrr.499 · DOI · Paper page
  21. Juhl, 2002, Bedtime administration of NN2211, a long-acting GLP-1 derivative, substantially reduces fasting and postprandial glycemia in type 2 diabetes., Diabetes, 51, 424, 10.2337/diabetes.51.2.424 · DOI · Paper page

Cited by

See all 198

Metadata

Authors
Matthews, J. E., Stewart, M. W., De Boever, E. H., Dobbins, R. L., Hodge, R. J., Walker, S. E., Holland, M. C., Bush, M. A., & for the Albiglutide Study Group
Venue
The Journal of Clinical Endocrinology & Metabolism
Published
2008-12-01
Volume
93
Issue
12
Pages
4810-4817
ISSN
  • 0021-972X (ISSN-L)
  • 1945-7197
OpenAlex
W2161551526
Cited by
198
References
11
FWCI
8.93
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Pharmacodynamics, Pharmacokinetics, Safety, and Tolerability of Albiglutide, a Long-Acting Glucagon-Like Peptide-1 Mimetic, in Patients with Type 2 Diabetes. https://app.cochat.ai/papers/10.1210/jc.2008-1518
The paper
Matthews, J. E., Stewart, M. W., De Boever, E. H., Dobbins, R. L., Hodge, R. J., Walker, S. E., Holland, M. C., Bush, M. A., & for the Albiglutide Study Group. (2008). Pharmacodynamics, Pharmacokinetics, Safety, and Tolerability of Albiglutide, a Long-Acting Glucagon-Like Peptide-1 Mimetic, in Patients with Type 2 Diabetes. The Journal of Clinical Endocrinology & Metabolism. https://doi.org/10.1210/jc.2008-1518

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.